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To elucidate the role of endogenous inducible nitric oxide (NO) on the regulation of NF-jB activity in
human chondrocytes, we evaluated (i) the pattern of expression of the neuronal (nNOS) and inducible
(iNOS) NO synthase isoforms and the basal NF-jB activity in normal and osteoarthritic (OA) human chon-
drocytes, (ii) the role of cytokines and growth factors in modulating the protein levels of the two NOS
isoforms, and (iii) the effect of inhibiting endogenous inducible NO production on the ability of interleu-
kin-1b (IL-1) to induce NF-jB activation. nNOS was more frequently expressed in normal than in OA
chondrocytes, whereas the opposite was found for iNOS. IL-1 induced the degradation of both enzymes,
but iNOS disappeared more rapidly. Although IjB-a was present in all the normal samples and in the
majority of the OA samples, NF-jB–DNA binding activity in OA chondrocytes was increased approxi-
mately twofold relatively to normal cells. Addition of a NOS inhibitor, after induction of iNOS expression,
induced IjB-a degradation and potenciated the effect of IL-1, indicating that endogenous inducible NO
inhibits NF-jB activation. Taken together, these findings favor an inhibitory role of high NO levels on
the regulation of NF-jB activation in chondrocytes, indicating that NF-jB activity is regulated, at least
in part, by the balanced production of NO resulting from a dynamic process that, at any given moment,
determines the availability of the constitutive and inducible NOS isoforms. Moreover, the down-regula-
tory role of NO on NF-jB activation warrants caution as to the possible utilization of NO inhibitors in the
therapy of OA.
 2008 Elsevier Inc. All rights reserved.Introduction of the NO synthase (iNOS or NOS II), whose expression is potentlyOsteoarthritis (OA)1 is a degenerative joint disease characterized
by extracellular matrix degradation and cartilage destruction,
accompanied by local inflammation and alterations of the subchon-
dral bone, being strongly associated with aging [1,2]. In fact, OA is
relatively uncommon before the age of 40 years old, increasing stee-
ply in prevalence thereafter [1,3].
Although the pathophysiology of OA is still incompletely under-
stood, nitric oxide (NO) seems to contribute to the development and
or progression of OA, namely bymediating some of the catabolic re-
sponses induced by pro-inflammatory and catabolic cytokines, like
interleukin-1b (IL-1), in chondrocytes [4–7]. The inducible isoformll rights reserved.
rosciences and Cell Biology,
ax: +351 239 480217.
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crosis factor-a.induced by pro-inflammatory cytokines through activation of the
transcription factor, nuclear factor-jB (NF-jB) [8], is responsible
for the production of large amounts of NO in articular chondrocytes,
both human and from other species [8–10]. Another NOS isoform,
neuronal NOS (nNOS or NOS I), which produces lower amounts of
NO, was found to be constitutively expressed in bovine chondro-
cytes and to be degraded in response to IL-1 [11]. The presence of
a protein similar in size and antibody binding to nNOS, but with
enzymatic activity characteristic of iNOS [12] has been reported in
human OA chondrocytes. It is still unclear which NOS isoforms are
expressed in normal and OA human chondrocytes.
Several lines of evidence indicate that NF-jB plays a crucial role
in OA, mediating important chondrocyte inflammatory responses
that ultimately lead to cartilage destruction [13]. However, the
mechanisms that regulate NF-jB activation, both in chondrocytes
and other cells, are still incompletely understood. In particular,
the question remains as to the role of NO on NF-jB activation
and the subsequent expression of its target genes. In various cells
from different species, NO has been shown to either induce [14–
16] or inhibit [11,17,18] NF-jB activation in response to a variety
S.C. Rosa et al. / Nitric Oxide 19 (2008) 276–283 277of stimuli. These and similar studies led to the conclusion that the
role of NO in modulating NF-jB activation is cell-type specific and
also depends on the experimental conditions. More recently, NO
has been shown to be able to both up- and down-regulate NF-jB
activity in murine macrophages, in a concentration- and time-
dependent manner [19]. In chondrocytes, either human or from
other species, studies directly addressing this issue are scarce
and the existing evidence, direct and indirect, points both to inhib-
itory [11,20] and up-regulatory actions [7,16].
Understanding the mechanisms that regulate NF-jB activity in
human chondrocytes, particularly the role of NO, will have impor-
tant implications for the development of new therapeutic strate-
gies for OA and other arthritic diseases. Furthermore,
understanding how the NO found in OA joints is generated is also
an important issue to define its role in the pathophysiology of the
disease and will provide relevant information to determine the po-
tential of therapeutically targeting the various NOS isoforms.
Aiming at contributing to elucidate these questions, this work
focused first in identifying the NOS isoforms present in normal
and OA human chondrocytes. Then, the basal NF-jB activity was
evaluated and compared with the pattern of expression of nNOS
and iNOS to determine whether these parameters are correlated,
either positive or negatively. To further elucidate the mechanisms
that regulate NO production in human OA chondrocytes and possi-
ble repercussions in the regulation of NF-jB activity, the ability of
cytokines and growth factors to modulate the levels of nNOS and
iNOS was studied. Finally and to directly determine the ability of
inducible NO to modulate NF-jB activity, IL-1-induced NF-jB acti-
vation was studied in the presence and absence of a general NOS
inhibitor.
Materials and methods
Cartilage samples
Human OA cartilage was removed from the remaining of the
distal femoral condyles obtained from patients (55–80 years old,
mean = 67) undergoing total knee replacement surgery at the
Orthopedic Department of the University Hospital of Coimbra
(HUC). All available cartilage was collected regardless of showing
normal appearance or including damaged areas. Normal human
knee cartilage was collected from the distal femoral condyles of
multi-organ donors (17–54 years old, mean = 36) within 24 h
post-mortem, at the Tissue Bank of HUC. Cartilage from all multi-
organ donors appeared normal without signs of fibrillation, rough
surface, erosion or any other changes. All the procedures had the
approval of the Ethics Committee of HUC.
Isolation and cell culture
Chondrocytes were isolated from the cartilage samples as de-
scribed previously [21]. Briefly, cartilage slices underwent sequen-
tial digestion with protease K (Sigma Chemical Co., St. Louis, MO,
USA) and collagenase (Roche, Indianapolis, IN, USA). To avoid chon-
drocyte dedifferentiation, non-proliferating monolayer cultures
were setup by plating 2  106 chondrocytes/ml in Ham F-12 med-
ium containing 3% antibiotic/antimycotic solution and 5% FBS and
allowed to recover for 24 h at 37 C in a humidified atmosphere
supplemented with 5% CO2. Prior to any treatments, the cells were
serum-starved overnight and thereafter maintained in culture
medium with 1% antibiotic/antimycotic solution, without serum.
Recombinant human IL-1b (Peprotech, Rocky Hill, NJ, USA) and/
or NG-Monomethyl-L-arginine acetate (L-NMMA) (Tocris Biosci-
ence, Avonmouth, UK) were added to the cell cultures for the peri-
ods indicated in the figure legends.Measurement of NO production
The basal NO production was measured as the amount of nitrite
accumulated in the supernatants of 16 h chondrocyte cultures not
submitted to any treatment. To evaluate the extent of inhibition of
NO production by L-NMMA, the culture medium from the chondro-
cyte cultures treated with IL-1 for 16 h was removed and replaced
by new medium. The cells were incubated for 2 h with or without
L-NMMA, followed by an additional 30 min incubation in the pres-
ence or absence of a second IL-1 stimulus. The culture mediumwas
collected and the concentration of nitrite in the cell-free culture
supernatants was measured using the spectrophotometric method
based on the Griess reaction.
Preparation of cytoplasmic and nuclear extracts
The cells were lysed in 150 ll of buffer 1 [10 mM Tris–HCl,
10 mM NaCl, 3 mM MgCl2, 0.5% Nonidet P-40, protease inhibitors
(Complete Mini, Roche, Indianapolis, IN, USA), pH 7.5] and incu-
bated on ice for 15 min. The lysates were centrifuged at 2300g/
5 min at 4 C and the supernatants (cytoplasmic extracts) were
stored at 20 C. The pellets were suspended in 25 ll of buffer 2
[20 mM HEPES, 5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 300 mM
NaCl, 20% glycerol, protease inhibitors (Complete Mini, Roche),
pH 7.5], incubated on ice for 20 min and centrifuged at 18,000g/
20 min at 4 C. The supernatants (nuclear extracts) were stored
at 20 C. The protein concentration was measured using the
bicinchoninic acid/copper (II) sulfate protein assay kit (Sigma
Chemical Co., St. Louis, MO, USA).
Western blot analysis
The cytoplasmic extracts were diluted in sodium dodecylsulfate
(SDS) sample buffer (2.5% SDS, 0.0625 M Tris–HCl, 10% glycerol, 5%
2-mercaptoethanol, 0.05% bromophenol blue, pH 6.8) and boiled
for 5 min at 95 C. Proteins (25 lg) were separated by SDS/PAGE
[10% (v/v)] and transferred onto PVDF membranes by electroblot-
ting. The membranes were blocked with 5% skim milk in Tris-buf-
fered Saline–Tween (TBS-T, 20 mM Tris–HCl, 150 Mm NaCl, 0.1%
Tween 20) and then probed with antibodies against nNOS, iNOS
(Abcam, Cambridge, UK) or IjB-a (Cell Signaling Technology, Inc.,
Danvers, MA, USA). After extensive washings with TBS-T, the blots
were incubated with an alkaline phosphatase-conjugated second-
ary antibody. Immunoreactive complexes were detected by chem-
ifluorescence using the ECF reagent (Amersham Biosciences,
Buckinghamshire, UK). Fluorescence was detected with a Storm
840 fluorescence scanner (Amersham Biosciences). To ensure a
roughly equal protein loading, mouse anti-actin monoclonal anti-
body (Chemicon International, Inc., Tremecula, CA, USA) was used
as internal control. The intensity of the bands was analyzed using
the ImageQuantTM TL software from Amersham Biosciences.
Electrophoretic mobility shift assay (EMSA)
An oligonucleotide probe corresponding to the NF-jB consen-
sus binding sequence (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) was end labeled with [c-32P]-ATP by the T4 polynucleotide
kinase (Amersham Pharmacia Biotech Inc., Piscatway, NJ, USA). Nu-
clear extracts (10 lg of protein) were incubated for 40 min at 4 C
in 20 ll binding reactions containing 100 mMHEPES, pH 7.9, 5 mM
MgCl2, 20% Ficoll 400, 2.5 mM DTT, 250 mM KCl, 500 lg/ml Poli-
dIdC, 5 mg/ml BSA, and 100,000 cpm/reaction of [c-32P]-labeled
oligonucleotide probe. The DNA–protein complexes were resolved
by electrophoresis in 7% native polyacrylamide gels in TBE 0.5 for
3 h at 150 V, dried and visualized by autoradiography. The specific
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TL software (Amersham Biosciences).
Data analysis
Where appropriate, statistical significance was assessed by the
unpaired Student’s t-test, performed using GraphPad Prism version
4.00 for Windows (GraphPad Software, San Diego, CA, USA,
www.graphpad.com).
Results
Expression of nNOS and iNOS in normal and OA chondrocytes
To characterize the sources of NO in normal and OA articular
chondrocytes, we evaluated the basal expression of nNOS and iNOS
in the cytoplasmic extracts of chondrocytes isolated from 26 OA
and from 6 normal cartilage samples. The supernatants of those
chondrocyte cultures were used to evaluate the basal NO produc-
tion. The relative level of each protein was calculated as the ratio
between the intensity of its band and that of the respective actin
band in the same membrane. The values obtained were plotted
against the normal or OA status of each sample.
The dot-plot in Fig. 1A shows that nNOS is present, in variable
amounts, in 17 (65.4%) of the 26 OA extracts and in 5 (83.3%) of
the 6 normal samples analyzed. The protein detected by Western
blot in normal and OA chondrocytes seems to be identical and
present in either type of sample as a single band or as doublet or
triplet bands. No specific band pattern could be ascribed to either
normal or OA chondrocytes. Despite the wide variation in the
amounts of nNOS found in distinct samples, either normal or OA,
the mean value in OA samples is lower than that obtained in nor-
mal chondrocytes, indicating a tendency of OA chondrocytes to ex-
press lower levels of nNOS.
On the other hand, iNOS was spontaneously expressed,
although in variable amounts, in 17 (65.4%) of the 26 OA samples,PCMW
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Fig. 1. Basal nNOS (A) and iNOS (B) expression in normal and OA chondrocytes. Dot-plots
in the cytoplasmic extracts of chondrocyte cultures established from 6 normal (N1–N6
primary non-proliferating chondrocyte cultures 16 h after an overnight serum-starvation
by Western blot. Each dot represents the ratio between the intensities of the nNOS or iN
shown are representative of samples, either normal or OA, positive or negative for nNObut in only 2 (33.3%) of the 6 normal samples analyzed (Fig. 1B).
Interestingly, these two samples were obtained from the older do-
nors, aged 48 and 54 years old. Although the cartilage from those 2
donors did not show evident macroscopic signs of arthritic lesions,
the possibility that OA was already in progress, especially at the
cellular and molecular levels, cannot be ruled out and may account
for the observed iNOS expression. Accordingly, iNOS was absent in
the remaining normal cartilage samples obtained from younger
donors, below the age of 40 years old.
Taken together, the results in Fig. 1 show that approximately
46% (12 out of 26) of the OA samples analyzed expressed both
NOS isoforms, almost 39% (10 out of 26) expressed either nNOS
(5 out of 26) or iNOS (5 out of 26) and 15% (4 out of 26) were neg-
ative for both isoforms. Furthermore, the dot-plots in Fig. 1 also
show a tendency of OA chondrocytes to express higher levels of
iNOS and lower levels of nNOS, relatively to normal chondrocytes.
The results obtained clearly distinguished nNOS from iNOS,
both in normal and OA chondrocytes. Nevertheless and to further
confirm the specificity of the antibodies used, the membranes ini-
tially probed with the anti-nNOS antibody were stripped and re-
probed with the anti-iNOS antibody which did not reveal any
band in the lane corresponding to the positive control for nNOS
(data not shown). Moreover, the pattern of nNOS expression in
the samples analyzed, either normal or OA, does not overlap with
that relative to iNOS expression. Actually, several samples, both
normal and OA, that express one of the isoforms, do not express
the other one, further confirming the specificity of the antibodies
used.
Significantly different concentrations of nitrite were found in
the supernatants of normal and OA chondrocytes cultures, depend-
ing on whether iNOS was expressed. The average nitrite concentra-
tion in the culture medium from normal or OA chondrocytes that
did not express iNOS was 3.6 ± 1.0 lM, whereas in cells expressing
iNOS it was 9.4 ± 2.9 lM (P < 0.01). Regardless of whether iNOS
was spontaneously expressed or not, treatment with IL-1, 20 ng/
ml, for 16 h increased NO production to 24.6 ± 5.4 lM. Therefore,P4MW P2P5MW
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Actin
P11MW
Normals Patients
MW N1 N6
150 kDa
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and representative Western blots showing the relative nNOS (A) and iNOS (B) levels
) and 26 OA (P1–P26) cartilage samples. Cytoplasmic extracts were prepared from
period that followed the initial culture in medium with 5% FBS (24 h), and analyzed
OS bands and the actin band for each sample in the same membrane. The images
S and iNOS. MW, molecular weight marker; PC, positive control.
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was significantly lower than that obtained upon stimulation with
IL-1, indicating that iNOS expression and activity in OA chondro-
cytes is sub-maximal.
NF-jB activity in normal and OA chondrocytes
Fig. 2 shows the presence of variable amounts of IjB-a in the
majority (88.5%) of the cytoplasmic extracts from OA chondrocytes
and in all the normal samples. Nevertheless, the mean relative lev-
els of IjB-a are lower in OA than in normal chondrocytes, although
a trend cannot clearly be drawn from the dot-plot shown in Fig. 2.
Since IjB-a was present in the majority of the OA samples, NF-
jB–DNA binding activity was assessed to determine, more specif-
ically, the basal NF-jB activation status. For this purpose, EMSA re-
sults were obtained in 12 OA and 5 normal samples. A small but
detectable NF-jB–DNA binding activity was present in the nuclear
extracts from all the normal chondrocyte cultures analyzed. There-
fore, NF-jB–DNA binding activity was considered to be increased
in the nuclear extracts from OA chondrocytes only when the inten-
sity of the corresponding complexes was higher than that observed
in the normal extracts analyzed in the same gel. Analysis of the
specific NF-jB–DNA complexes showed increased NF-jB activity
in approximately 90% (11 out of 12 samples) of the nuclear extracts
from OA chondrocytes. Furthermore, the average intensity of the
complexes detected in those 11 OA samples (1.82 ± 0.23) is signif-
icantly higher than the intensity of the complexes detected in the
normal samples (0.91 ± 0.05) (Fig. 3A). Fig. 3B shows EMSA auto-
radiographies representative of the NF-jB activation status in nor-
mal and OA chondrocytes.
Comparison of the NF-jB activation status with the presence or
absence of the NOS isoforms shows increased activity of this tran-
scription factor in all the nuclear extracts from OA chondrocytes
that also express iNOS (n = 9), either alone (n = 3) or in conjunctionNormals Patients
N4 N6MW MW37 kDa
50 kDa
IκB-α
Actin
P19
37 kDa
MW
50 kDa
P1 P7
IκB-α
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Fig. 2. Basal IjB-a expression in normal and OA chondrocytes. Dot-plot and
representative Western blots showing the relative IjB-a levels in the cytoplasmic
extracts of chondrocyte cultures established from 6 normal (N1–N6) and 26 OA
(P1–P26) cartilage samples. Cytoplasmic extracts were prepared from primary non-
proliferating chondrocyte cultures 16 h after an overnight serum-starvation period
that followed the initial culture in medium with 5% FBS (24 h), and analyzed by
Western blot. Each dot represents the ratio between the intensities of the IjB-a and
the actin bands for each sample in the same membrane. The images shown are
representative of samples, either normal or OA, positive or negative for IjB-a. MW,
molecular weight marker.
Free Oligo.>
Fig. 3. Basal NF-jB activity in normal and OA chondrocytes. Nuclear extracts were
prepared from primary non-proliferating chondrocyte cultures 16 h after an
overnight serum-starvation period that followed the initial culture in medium
with 5% FBS (24 h). (A) The intensity of the specific NF-jB–DNA complexes in
normal and OA nuclear extracts was normalized to that of the corresponding non-
specific complexes. The bars represent means ± SEM of the results obtained with
the nuclear extracts from 5 normal and 12 OA samples, respectively. *P < 0.05. (B
Representative autoradiography of the results depicted in A.)with nNOS (n = 6). Increased NF-jB–DNA complexes were also
found in the nuclear extract from one sample in which both NOS
isoforms were absent and in another one that lacked iNOS, but
not nNOS. The only sample in which NF-jB activity was not in-
creased, expressed nNOS but not iNOS.
Interestingly, IjB-awas detected in the majority of the OA sam-
ples analyzed, including those that showed increased NF-jB–DNA
binding activity.
Modulation of nNOS and iNOS protein levels by IL-1b
To further elucidate the mechanisms that regulate NO produc-
tion in human OA chondrocytes and possible repercussions in the
modulation of NF-jB activity, nNOS and iNOS levels were
evaluated in the cytoplasmic extracts of OA chondrocyte cultures
treated with the pro-inflammatory and catabolic cytokines, IL-1
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280 S.C. Rosa et al. / Nitric Oxide 19 (2008) 276–283(20 ng/ml) and tumor necrosis factor-a (TNF-a, 20 ng/ml), and
with the anabolic growth factors, insulin-like growth factor-1
(IGF-1, 100 ng/ml), and transforming growth factor-b (TGF-b,
10 ng/ml), for various periods of time.
Fig. 4 shows significantly decreased levels of nNOS in OA cells
treated with IL-1 for 16 h (55.1 ± 7.3%), relatively to control
untreated cells, whereas treatment for shorter periods (5 or
30 min) had no effect (97.4 ± 3.4% and 104.9 ± 12.3%, respec-
tively). Treatment with TNF-a also induced nNOS disappearance
(data not shown). Neither IL-1 nor TNF-a was capable of induc-
ing nNOS synthesis for up to 48 h treatment (data not shown).
iNOS protein levels in OA chondrocytes decreased to
45.4 ± 10.6% of the control upon treatment with IL-1 for only
15 min, and were further reduced to 41.5 ± 3.3% when the treat-
ment period was extended to 2 h (Fig. 5B.1). On the other hand,
treatment with this cytokine for 16 h significantly increased iNOS
levels to 429.4 ± 74.6% of the control. Furthermore, in OA chondro-
cyte cultures that did not express iNOS spontaneously, treatment
with IL-1 for 16 h was also effective in inducing its expression
(Fig. 5B.2), indicating that its absence, in untreated cells, is not
due to a permanent inhibition of its expression or induction of
its degradation. Moreover, treatment of the chondrocyte cultures
with TNF-a induced iNOS disappearance and synthesis in the same
manner as IL-1 (data not shown).
On the other hand, treatment with IGF-1 or TGF-b, for up to
48 h, had no effect on the levels of either nNOS or iNOS, regardless
of their presence or absence in basal conditions (data not shown).nNOS
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Fig. 4. nNOS levels in the cytoplasmic extracts from OA chondrocyte cultures
treated with IL-1, 20 ng/ml, for the periods indicated. (A) Each bar represents the
intensity (in percentage relative to the control) of the bands corresponding to nNOS
normalized to the respective actin band. The results shown are means ± SEM of, at
least, three independent experiments. *P < 0.05. (B) The images shown are repre-
sentative of the results obtained with, at least, three distinct OA cartilage samples
for each treatment period.
Actin
Fig. 5. iNOS levels in the cytoplasmic extracts from OA chondrocyte cultures
treated with IL-1, 20 ng/ml, for the periods indicated. (A) Each bar represents the
intensity (in percentage relative to the control) of the bands corresponding to iNOS
normalized to the respective actin band. The results shown are means ± SEM of
three independent experiments. *P < 0.05 and **P < 0.01. (B) The images shown are
representative of the responses to IL-1 of OA chondrocyte cultures that did (B.1) or
did not (B.2) express iNOS spontaneously.Role of endogenous inducible NO on IL-1-induced NF-jD activation
To more directly elucidate whether NO, produced endogenously
by iNOS, can modulate NF-jB activation, chondrocyte cultures
were treated with IL-1, 20 ng/ml, for 16 h to induce iNOS expres-
sion and the subsequent NO production. Then, the cells were incu-
bated for 2 h in the presence or absence of L-NMMA, a general NOS
inhibitor, followed by an additional 30 min incubation in the pres-
ence or absence of a second IL-1 stimulus (20 ng/ml) to induce NF-
jB activation. Measurement of the nitrite concentration in the cul-
ture supernatants confirmed that treatment with L-NMMA,
250 lM, reduced IL-1-induced NO production by approximately
50% (data not shown) relatively to the cells treated with IL-1 for
16 h and thereafter left untreated.
IjB-a levels in cells treated only with the first IL-1 stimulus
were identical to those detected in untreated cells (Fig. 6A). As ex-
pected, treatment with IL-1 for 30 min, in the absence of L-NMMA,
reduced IjB-a levels to 65.0 ± 3.5% of those found in cells treated
only with the first IL-1 stimulus, indicating that NF-jB had been
activated (Fig. 6A). On the other hand, in cells treated with L-
NMMA, but not with the second IL-1 stimulus, IjB-a levels de-
creased to 56.0 ± 3.4%. No significant difference was found be-
tween IjB-a levels in cells treated only with the second IL-1
stimulus or with L-NMMA alone. Addition of the second IL-1 stim-
ulus to chondrocyte cultures in the presence of L-NMMA further re-
duced IjB-a levels to 42.5 ± 2.9% (Fig. 6A), indicating that the
presence of the NOS inhibitor facilitated IL-1-induced IjB-a
degradation.
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Fig. 6. Role of NO on IL-1-induced NF-jB activation. (A) IjB-a levels in the cytoplasmic extracts of articular chondrocyte cultures untreated or treated with IL-1, 20 ng/ml, for
16 h to induce iNOS expression, followed by treatment for 2 h in the presence or absence of L-NMMA and an additional 30 min incubation in the presence or absence of a
second IL-1 stimulus (20 ng/ml) to induce NF-jB activation. Each bar represents the intensity (in percentage relative to cells treated only with IL-1, 20 ng/ml, for 16 h) of the
bands corresponding to IjB-a normalized to the respective actin band. (B) The corresponding nuclear extracts were used to detect NF-jB–DNA binding by EMSA. Each bar
represents the intensity of the specific NF-jB–DNA complexes in each sample normalized to that of the corresponding non-specific complexes. The autoradiographies shown
are representative of, at least, three independent experiments. The results presented in A and B are means ± SEM of, at least, three independent experiments. *P < 0.05 and
**P < 0.01.
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sponding nuclear extracts. Fig. 6B shows that the intensity of the
specific NF-jB–DNA complexes is identical in untreated cells and
in those treated only with the first IL-1 stimulus, but increased sig-
nificantly in cells treated with the second IL-1 stimulus in the ab-
sence of L-NMMA (133.3 ± 12.3%). The intensity of the specific NF-
jB–DNA complexes was further increased in cells treated with the
second IL-1 stimulus in the presence of that inhibitor(179.7 ± 6.4%). Furthermore, treatment with L-NMMA alone was
sufficient to increase the intensity of the specific NF-jB–DNA com-
plexes by approximately 25% relatively to the cells treated only
with the first IL-1 stimulus.
Taken together, the results in Fig. 6 show increased IjB-a
degradation and NF-jB–DNA binding activity in cells treated
with IL-1 in the presence of L-NMMA, suggesting that lower
NO levels facilitate NF-jB activation, or conversely, that the
282 S.C. Rosa et al. / Nitric Oxide 19 (2008) 276–283presence of NO contributes to limit the activation of this tran-
scription factor.Discussion
The results obtained (Fig. 1) show that normal and OA chondro-
cytes differentially express nNOS and iNOS, the first being more
frequently present in normal chondrocytes, whereas iNOS
prevailed in OA chondrocytes. These results suggest that normal
human articular chondrocytes constitutively express nNOS, which
is in agreement with our previous studies in bovine chondrocytes
[11], but in contrast with those reported by Amin and co-workers
[12] who found a NOS protein similar to nNOS only in OA chondro-
cytes. However, the protein identified in the later study produced
large amounts of NO, which is a distinctive feature of iNOS, and
it is not clear whether that protein is identical to nNOS, a modifi-
cation of iNOS, or even a novel NOS isoenzyme [22]. On the other
hand, in our study, one or two bands with apparent molecular
weights lower than that characteristic of nNOS and that reacted
with the anti-nNOS antibody were detected in some samples, both
normal and OA. Those bands may represent partially degraded
forms of the typical nNOS enzyme or may correspond to different
nNOS protein isoforms resulting from alternative mRNA splicing.
These are, in fact, two major forms of post-transcriptional regula-
tion of nNOS, although the determinants or mechanisms that reg-
ulate those events and their biological significance are yet poorly
understood [23]. Further studies are required to fully characterize,
at the molecular level, the bands detected and to assess their bio-
logical significance.
Although the present study did not intend to be quantitative,
but rather to detect the presence or absence of the two NOS iso-
forms, the dot-plots in Fig. 1 clearly show that the amount of each
of these proteins present in different samples is highly variable.
This variability suggests that the mechanisms regulating nNOS
and iNOS in articular chondrocytes differ considerably between
OA patients, possibly reflecting differences in the evolution of the
disease process. In fact, even though all the patients had advanced
OA, with extensive erosion demanding total knee replacement sur-
gery, the cartilage still remaining showed marked macroscopic dif-
ferences (for instance, in stiffness or tenderness) between patients,
suggesting that the evolution of the disease process is not uniform
among patients.
The results obtained in this study show increased NF-jB activ-
ity in samples that also expressed iNOS (Fig. 3). Thus, a tempting
explanation would be that the NO being produced would sustain
NF-jB activation. However, we also found increased NF-jB activity
in chondrocytes that did not express iNOS or even nNOS. Further-
more, Fig. 6 shows that even a partial reduction of the endogenous
inducible NO production is sufficient to induce IjB-a degradation
and NF-jB–DNA binding activity and to potenciate the effects of
IL-1. These results are in agreement with our previous studies in
bovine chondrocytes in which addition of a NO donor to the cell
cultures decreased IL-1-induced NF-jB activity and iNOS expres-
sion [11].
However, another study in which bovine chondrocytes were
used, showed that NO is required to sustain lipopolysaccharide
and cytokine-induced NF-jB activation [16]. Since bovine chon-
drocytes constitutively express nNOS, but not iNOS [11], and L-
NMMA was added concomitantly or shortly after the LPS and cyto-
kine mixture, the effects reported in that study can only be attrib-
uted to inhibition of nNOS activity, implying that constitutive NO
or low concentrations of NO have an up-regulatory effect on NF-
jB activity. In the current study, L-NMMA was added to the chon-
drocyte cultures after induction of iNOS expression, and as such it
evaluated mainly the contribution of inducible NO or high concen-trations of NO, indicating that high levels of NO restrain NF-jB
activation. Taken together, these studies suggest that high and
low NO concentrations exert opposite effects on NF-jB activation
in chondrocytes. This is in agreement with a study in murine mac-
rophages that first reported the dual effect of NO on NF-jB activa-
tion, showing that small amounts of NO, as those produced by the
constitutive NOS isoforms, facilitated and high concentrations,
resulting from iNOS activity, inhibited NF-jB activation [19]. How-
ever, significant differences may exist between bovine and human
chondrocytes. In fact, we found that IL-1-induced nNOS degrada-
tion occurs more rapidly in bovine chondrocytes [11] than in hu-
man cells (Fig. 4), which may contribute to species differences as
to the role of constitutive NO in modulating NF-jB activation in
chondrocytes.
One possible mechanism contributing to the dual role of NO on
NF-jB activation is the intracellular redox potential of the cells,
since it determines the type of redox-end products of NO that
can be generated in a given moment or in certain conditions
[24]. Indeed, the two major redox derivatives of NO, peroxynitrite
and S-nitrosothiol, have been shown to exert opposite effects on
NF-jB activation [15,25]. More recently, other mechanisms by
which NO can modulate, negative or positively, NF-jB activity
have been identified [26,27], but their relevance in different cells
and under distinct conditions and stimuli remains to be elucidated.
On the other hand, the expression and regulation of the consti-
tutive and inducible NOS isoforms are crucial determinants of
time-dependent changes in NO concentration and thus on NF-jB
activity. Pro-inflammatory stimuli were proposed to generate
those time-dependent changes by promoting the differential
expression of the constitutive and inducible NOS isoforms [19].
The ability of IL-1 to induce the disappearance of both nNOS and
iNOS found in the present study (Figs. 4 and 5) is in agreement
with this hypothesis.
Studies in other cells demonstrated that degradation is an
important mechanism whereby both nNOS and iNOS are regulated
[28,29]. The current study indicates that degradation is also in-
volved in the regulation of nNOS and iNOS in human chondrocytes
and probably contributes to the variable amounts of these en-
zymes found among OA chondrocytes. Since iNOS expression is in-
duced by inflammatory cytokines, like IL-1, its concentration in
chondrocytes, at any given moment, probably results from the bal-
ance between the rates of synthesis and degradation, determined,
at least in part, by the availability of cytokines. On the other hand,
nNOS regulation by cytokines seems to depend mainly on its deg-
radation, since neither IL-1 nor TNF-a was capable of inducing its
synthesis, but both cytokines induced its degradation (Fig. 4 and
data not shown). Furthermore, since the anabolic growth factors,
IGF-1 and TGF-b, had no effect on the levels of either nNOS or iNOS
(data not shown), at least in the conditions tested, it seems that
pro-inflammatory cytokines are the major regulators of NOS iso-
forms in human chondrocytes.
In terms of NO production, the consequence of this process is
that the action of pro-inflammatory cytokines, like IL-1 or TNF-a,
in chondrocytes can lead, in the short term, to a low NO production
due to the activity of the eventually existing nNOS, since iNOS,
even if previously expressed, rapidly disappears. Thus, the low
NO levels, produced by nNOS, can favor or, at least, not affect,
NF-jB activation and the subsequent expression of iNOS and other
NF-jB-dependent genes. Newly synthesized iNOS then leads to an
increased NO production which can terminate NF-jB activation
until a new stimulus restarts the process.
Considering the osteoarthritic joint, this suggests that a dy-
namic equilibrium can be established in which the levels of NO
and pro-inflammatory cytokines are mutually regulated, contribut-
ing to sustain over time, a low to moderate level of NF-jB activity
and NF-jB-dependent gene expression. Indeed, NF-jB regulates
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found in the OA joint, like IL-1, TNF-a and IL-18, which in turn, in-
duce its activation [30,31]. In the absence of regulatory mecha-
nisms, this might lead to a positive feed-back process in which
high NF-jB activity and expression of pro-inflammatory genes,
including iNOS and pro-inflammatory cytokines, were maintained.
Instead, OA is characterized by a low grade inflammation [32] in
which the cytokine and nitrite levels (reflecting NO production)
in the joint are much lower than those found in inflammatory
types of arthritis [33,34]. This suggests that, in OA, NF-jB is not
fully activated, but rather maintained in a state of moderate activ-
ity. The presence of detectable amounts of the NF-jB inhibitor,
IjB-a, in the cytoplasmic extracts of the majority of the OA sam-
ples analyzed (Fig. 2), including those that showed increased NF-
jB activity (Fig. 3), and the moderate NO production, even in chon-
drocytes that expressed iNOS, further support this hypothesis. The
observed inhibitory effect of iNOS-derived NO on IL-1-induced NF-
jB activity (Fig. 6) together with the cytokine-induced degradation
of nNOS and iNOS provide a mechanism by which pro-inflamma-
tory cytokines and NF-jB can be sustained in a state of moderate
activity, contributing to the perpetuation of the low grade inflam-
mation characteristic of OA, but preventing the occurrence of an
exacerbated inflammatory response.
In summary, this study shows that OA chondrocytes, relatively
to normal cells, tend to express iNOS and less frequently nNOS and
to present moderate spontaneous NF-jB activity, which seems to
be regulated, at least in part, by the balanced production of NO
resulting from a dynamic process that, at any givenmoment, deter-
mines the availability of the constitutive and inducible NOS iso-
forms. The findings presented favor an inhibitory role of high
amounts of NO on NF-jB activity in chondrocytes and reconcile
observations, so far, apparently contradictory [11,16]. Moreover,
the down-regulatory role of NO on NF-jB activation warrants cau-
tion as to the possible utilization of NOS inhibitors in the therapy of
OA.
Acknowledgments
The authors wish to thank Dr. Maria Teresa Cruz, professor at
the Faculty of Pharmacy and researcher at the Center for Neurosci-
ences and Cell Biology, University of Coimbra, Portugal, for the crit-
ical review of this manuscript. Rosa S.C. is supported by a Ph.D.
fellowship (SFRH/BD/19763/2004) from the Portuguese Founda-
tion for Science and Technology (FCT). This work was supported
by Grant PTDC/SAU-OSM/67936/2006 from FCT.
References
[1] T. Aigner, J. Haag, J. Martin, J. Buckwalter, Osteoarthritis: aging of matrix and
cells—going for a remedy, Curr. Drug Targets 8 (2007) 325–331.
[2] M.B. Goldring, Update on the biology of the chondrocyte and new approaches
to treating cartilage diseases, Best Practice Res. Clin. Rheumatol. 20 (2006)
1003–1025.
[3] J.A. Buckwalter, J.A. Martin, Osteoarthritis, Adv. Drug Delivery Rev. 58 (2006)
150–167.
[4] H.J. Hauselmann, L. Oppliger, B.A. Michel, M. Stefanovic-Racic, C.H. Evans,
Nitric oxide and proteoglycan biosynthesis by human articular chondrocytes in
alginate culture, FEBS Lett. 352 (1994) 361–364.
[5] Y.Y. Lo, J.A. Conquer, S. Grinstein, T.F. Cruz, Interleukin-1b induction of c-fos
and collagenase expression in articular chondrocytes: involvement of reactive
oxygen species, J. Cell Biochem. 69 (1998) 19–29.
[6] F.J. Blanco, R.L. Ochs, H. Schwarz, M. Lotz, Chondrocyte apoptosis induced by
nitric oxide, Am. J. Pathol. 146 (1995) 75–85.
[7] F.J. Blanco, M. Lotz,IL-1-induced nitric oxide inhibits chondrocyte proliferation
via PGE2, Exp. Cell Res. 218 (1995) 319–325.[8] A.F. Mendes, M.M. Caramona, A.P. Carvalho, M.C. Lopes, Role of mitogen-
activated protein kinases and tyrosine kinases on IL-1-induced NF-jB
activation and iNOS expression in bovine articular chondrocytes, Nitric
Oxide 6 (2002) 35–44.
[9] R.M. Palmer, M.S. Hickery, I.G. Charles, S. Moncada, M.T. Bayliss, Induction of
nitric oxide synthase in human chondrocytes, Biochem. Biophys. Res.
Commun. 193 (1993) 398–405.
[10] J. Stadler, M. Stefanovic-Racic, T.R. Billiar, R.D. Curran, L.A. McIntyre, H.I.
Georgescu, R.L. Simmons, C.H. Evans, Articular chondrocytes synthesize nitric
oxide in response to cytokines and lipopolysaccharide, J. Immunol. 147 (1991)
3915–3920.
[11] A.F. Mendes, A.P. Carvalho, M.M. Caramona, M.C. Lopes, Role of nitric oxide in
the activation of NF-jB, AP-1 and NOS II expression in articular chondrocytes,
Inflamm. Res. 51 (2002) 369–375.
[12] A.R. Amin, P.E. Di Cesare, P. Vyas, M. Attur, E. Tzeng, T.R. Billiar, S.A. Stuchin,
S.B. Abramson, The expression and regulation of nitric oxide synthase in
human osteoarthritis-affected chondrocytes: evidence for up-regulated
neuronal nitric oxide synthase, J. Exp. Med. 182 (1995) 2097–2102.
[13] J.A. Roman-Blas, S.A. Jimenez, NF-jB as a potential therapeutic target in
osteoarthritis and rheumatoid arthritis, Osteoarthritis Cartilage 14 (2006)
839–848.
[14] H. Muhl, J. Pfeilschifter, Amplification of nitric oxide synthase expression by
nitric oxide in interleukin 1b-stimulated rat mesangial cells, J. Clin. Invest. 95
(1995) 1941–1946.
[15] C. Zouki, L. Jozsef, S. Ouellet, Y. Paquette, J.G. Filep, Peroxynitrite mediates
cytokine-induced IL-8 gene expression and production by human leukocytes,
J. Leukoc. Biol. 69 (2001) 815–824.
[16] R.M. Clancy, P.F. Gomez, S.B. Abramson, Nitric oxide sustains nuclear factor jB
activation in cytokine-stimulated chondrocytes, Osteoarthritis Cartilage 12
(2004) 552–558.
[17] M. Colasanti, T. Persichini, M. Menegazzi, S. Mariotto, E. Giordano, C.M.
Caldarera, V. Sogos, G.M. Lauro, H. Suzuki, Induction of nitric oxide synthase
mRNA expression. Suppression by exogenous nitric oxide, J. Biol. Chem. 270
(1995) 26731–26733.
[18] S.K. Park, H.L. Lin, S. Murphy, Nitric oxide regulates nitric oxide synthase-2
gene expression by inhibiting NF-jB binding to DNA, Biochem. J. 322 (1997)
609–613.
[19] L. Connelly, M. Palacios-Callender, C. Ameixa, S. Moncada, A.J. Hobbs, Biphasic
regulation of NF-jB activity underlies the pro- and anti-inflammatory actions
of nitric oxide, J. Immunol. 166 (2001) 3873–3881.
[20] Y.E. Henrotin, S.X. Zheng, G.P. Deby, A.H. Labasse, J.M. Crielaard, J.Y. Reginster,
Nitric oxide downregulates interleukin 1b (IL-1b) stimulated IL-6, IL-8, and
prostaglandin E2 production by human chondrocytes, J. Rheumatol. 25 (1998)
1595–1601.
[21] T.F. Cruz, G. Mills, K.P.H. Pritzker, R.A. Kandel, Inverse correlation between
tyrosine phosphorylation and collagenase production in chondrocytes,
Biochem. J. 269 (1990) 717–721.
[22] K. Vuolteenaho, T. Moilanen, N. Al-Saffar, R.G. Knowles, E. Moilanen,
Regulation of the nitric oxide production resulting from the glucocorticoid-
insensitive expression of iNOS in human osteoarthritic cartilage, Osteoarthritis
Cartilage 9 (2001) 597–605.
[23] W.K. Alderton, C.E. Cooper, R.G. Knowles, Nitric oxide synthases: structure,
function and inhibition, Biochem. J. 357 (2001) 593–615.
[24] R.M. Clancy, A.R. Amin, S.B. Abramson, The role of nitric oxide in inflammation
and immunity, Arthritis Rheum 41 (1998) 1141–1151.
[25] H.E. Marshall, J.S. Stamler, Inhibition of NF-jB by S-nitrosylation, Biochemistry
40 (2001) 1688–1693.
[26] S. Mariotto, Y. Suzuki, T. Persichini, M. Colasanti, H. Suzuki, O. Cantoni, Cross-
talk between NO and arachidonic acid in inflammation, Curr. Med. Chem. 14
(2007) 1940–1944.
[27] V.A. Yakovlev, I.J. Barani, C.S. Rabender, S.M. Black, J.K. Leach, P.R. Graves, G.E.
Kellogg, R.B. Mikkelsen, Tyrosine nitration of IjB-a: a novel mechanism for
NF-jB activation, Biochemistry 46 (2007) 11671–11683.
[28] P.J. Kolodziejski, A. Musial, J.S. Koo, N.T. Eissa, Ubiquitination of inducible nitric
oxide synthase is required for its degradation, Proc. Natl. Acad. Sci. USA 99
(2002) 12315–12320.
[29] A. Musial, N.T. Eissa, Inducible nitric-oxide synthase is regulated by the
proteasome degradation pathway, J. Biol. Chem. 276 (2001) 24268–24273.
[30] S. Ghosh, M. Karin, Missing pieces in the NF-jB puzzle, Cell 109 (2002) S81–
S96.
[31] H.L. Pahl, Activators and target genes of Rel/NF-jB transcription factors,
Oncogene 18 (1999) 6853–6866.
[32] J.C. Fernandes, J. Martel-Pelletier, J.P. Pelletier, The role of cytokines in
osteoarthritis pathophysiology, Biorheology 39 (2002) 237–246.
[33] M.N. Farahat, G. Yanni, R. Poston, G.S. Panayi, Cytokine expression in synovial
membranes of patients with rheumatoid arthritis and osteoarthritis, Ann.
Rheum. Dis. 52 (1993) 870–875.
[34] V. Moos, S. Fickert, B. Müller, U. Weber, J. Sieper, Immunohistological analysis
of cytokine expression in human osteoarthritic and healthy cartilage, J.
Rheumatol. 26 (1999) 870–879.
